Takeda presents promising data for TAK-861 at SLEEP 2024

4 June 2024
takeda_hq_japan_large

Japanese pharma major Takeda (TYO: 4502) has presented positive results from its Phase IIb trial of TAK-861 at the SLEEP 2024 annual meeting.

The firm is testing the therapy in narcolepsy type 1 (NT1), a chronic, rare neurological central disorder.

NT1 is caused by a significant loss of orexin neurons, and there are currently no approved treatments targeting the underlying pathophysiology of the condition.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical